| Chronic stress primes innate immune responses in mice and humans TJ Barrett, EM Corr, C van Solingen, F Schlamp, EJ Brown, GJ Koelwyn, ... Cell reports 36 (10), 2021 | 93 | 2021 |
| Von Willebrand disease mutation spectrum and associated mutation mechanisms A de Jong, J Eikenboom Thrombosis research 159, 65-75, 2017 | 83 | 2017 |
| Developments in the diagnostic procedures for von Willebrand disease A De Jong, J Eikenboom Journal of Thrombosis and Haemostasis 14 (3), 449-460, 2016 | 82 | 2016 |
| Increased DUX4 expression during muscle differentiation correlates with decreased SMCHD1 protein levels at D4Z4 J Balog, PE Thijssen, S Shadle, KR Straasheijm, PJ van der Vliet, ... Epigenetics 10 (12), 1133-1142, 2015 | 71 | 2015 |
| Long noncoding RNA CHROMR regulates antiviral immunity in humans C van Solingen, Y Cyr, KR Scacalossi, M de Vries, TJ Barrett, A de Jong, ... Proceedings of the National Academy of Sciences 119 (37), e2210321119, 2022 | 28 | 2022 |
| Correction of a dominant‐negative von Willebrand factor multimerization defect by small interfering RNA‐mediated allele‐specific inhibition of mutant von Willebrand factor A de Jong, RJ Dirven, JA Oud, D Tio, BJM van Vlijmen, J Eikenboom Journal of Thrombosis and Haemostasis 16 (7), 1357-1368, 2018 | 25 | 2018 |
| Variability of von Willebrand factor‐related parameters in endothelial colony forming cells A de Jong, E Weijers, R Dirven, S de Boer, J Streur, J Eikenboom Journal of Thrombosis and Haemostasis 17 (9), 1544-1554, 2019 | 24 | 2019 |
| Endothelial characteristics in healthy endothelial colony forming cells; generating a robust and valid ex vivo model for vascular disease S de Boer, M Bowman, C Notley, A Mo, P Lima, A de Jong, R Dirven, ... Journal of Thrombosis and Haemostasis 18 (10), 2721-2731, 2020 | 23 | 2020 |
| Ex vivo improvement of a von Willebrand disease type 2A phenotype using an allele-specific small-interfering RNA A de Jong, RJ Dirven, J Boender, F Atiq, SY Anvar, FWG Leebeek, ... Thrombosis and haemostasis 120 (11), 1569-1579, 2020 | 18 | 2020 |
| Characterization of large in-frame von Willebrand factor deletions highlights differing pathogenic mechanisms A Cartwright, SJ Webster, A de Jong, RJ Dirven, LDS Bloomer, ... Blood advances 4 (13), 2979-2990, 2020 | 9 | 2020 |
| Small interfering RNA–mediated allele-selective silencing of von Willebrand factor in vitro and in vivo YK Jongejan, E Schrader Echeverri, RJ Dirven, K Paunovska, ... Blood Advances 7 (20), 6108-6119, 2023 | 8 | 2023 |
| Identification of von Willebrand factor D4 domain mutations in patients of Afro‐Caribbean descent: In vitro characterization MD Dubois, I Peyron, ON Pierre‐Louis, S Pierre‐Louis, J Rabout, ... Research and Practice in Thrombosis and Haemostasis 6 (4), e12737, 2022 | 2 | 2022 |
| Use of “C9/11 Mismatch” Control siRNA Reveals Sequence-Related Off-Target Effect on Coagulation of an siRNA Targeting Mouse Coagulation Factor XII M Heestermans, A de Jong, S van Tilburg, PH Reitsma, HH Versteeg, ... nucleic acid therapeutics 29 (4), 218-223, 2019 | 1 | 2019 |
| Personalized treatment for von Willebrand disease by RNA-targeted therapies A Jong Leiden University, 2020 | | 2020 |
Henri M.H. SpronkAssociate Professor Biochemistry, Maastricht University在 maastrichtuniversity.nl 的电子邮件经过验证
